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Background and objective: Recessive mutations in the SIL1 gene cause
Marinesco-Sjögren syndrome (MSS), a rare neuropediatric disorder. MSS-patients
typically present with congenital cataracts, intellectual disability, cerebellar ataxia and
progressive vacuolar myopathy. However, atypical clinical presentations associated with
SIL1 mutations have been described over the last years; compound heterozygosity of
SIL1 missense mutations even resulted in a phenotype not fulfilling the clinical diagnostic
criteria of MSS. Thus, a read-out system to evaluate reliably the pathogenicity of amino
acid changes in SIL1 is needed. Here, we aim to provide suitable cellular biomarkers
enabling the robust evaluation of pathogenicity of SIL1 mutations.
Methods: Five SIL1 variants including one polymorphism (p.K132Q), three known
pathogenic mutations (p.V231_I232del, p.G312R, and p.L457P) and one ambiguous
missense variant (p.R92W) were studied along with the wild-type proteins in Hek293
in vitro models by cell biological assays, immunoprecipitation, immunoblotting, and
immunofluorescence as well as electron microscopy. Moreover, the SIL1-interactomes
were interrogated by tandem-affinity-purification and subsequent mass spectrometry.
Results: Our combined studies confirmed the pathogenicity of p.V231_I232del,
p.G312R, and p.L457P by showing instability of the proteins as well as tendency
to form aggregates. This observation is in line with altered structure of the ER-Golgi
system and vacuole formation upon expression of these pathogenic SIL1-mutants
as well as the presence of oxidative or ER-stress. Reduced cellular fitness along
with abnormal mitochondrial architecture could also be observed. Notably, both
the polymorphic p.K132Q and the ambiguous p.R92W variants did not elicit
such alterations. Study of the SIL1-interactome identified POC1A as a novel
binding partner of wild-type SIL1; the interaction is disrupted upon the presence
of pathogenic mutants but not influenced by the presence of benign variants.
Disrupted SIL1-POC1A interaction is associated with centrosome disintegration.
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Conclusions: We developed a combination of cellular outcome measures to evaluate
the pathogenicity of SIL1 variants in suitable in vitro models and demonstrated that
the p. R92W missense variant is a polymorphism rather than a pathogenic mutation
leading to MSS.
Keywords: SIL1-interactome, Marinesco-Sjögren syndrome biomarkers, SIL1 missense mutation, POC1A,
FAM134B, centrosome
INTRODUCTION
Marinesco-Sjögren syndrome (MSS) was established as an entity
by the Romanian neurologist Georges Marinesco in 1931 based
on the description of four individuals from a single family
presenting with ataxia, cataracts, intellectual disability, and
myopathy. This was followed by Torsten Sjögren who further
defined the original four cases as well as 10 additional patients.
Afterwards, cerebellar atrophy was described as part of the
phenotypic spectrum (1). In 2005, two groups independently
reported recessive mutations in the SIL1 gene as the major
genetic cause for MSS (2, 3). SIL1 encodes a co-chaperone for
the major Endoplasmic Reticulum (ER)-resident chaperone BiP
and thus controls a variety of BiP-dependent functions such as
protein folding (4). Hereby, SIL1 acts as a N-linked glycoprotein
equipped with an N-terminal ER targeting sequence and a C-
terminal ER retention signal. SIL1 dimerises at the N-terminus
into a clamp-like configuration that interacts with the BiP ATPase
domain and causes substrate release of BiP via the release of
ADP (5).
The “clinical triad” of MSS is defined by presence of
bilateral cataracts, ataxia, and myopathy whereas intellectual
disability can manifest with very varying degree or can even
be absent (6). So far, a clear genotype-phenotype correlation
does not exist, and the phenotypical presentation becomes
even more complex by the description of additional features:
pectus carinatum and bilateral clinodactyly in a patient
with a homozygous large indel in the 5
′
UTR (7), Dandy-
Walker malformations in a Chinese family with a non-stop
mutation (8) and associated motor neuronopathy with a
bradykinetic movement disorder in a 5-year-old child, suggesting
an intriguing continuum between neurodevelopmental and
neurodegenerative multisystem disorders intricately linked in
the same cellular pathways (9). Moreover, the phenotypical
variation has become even more complex by the first report
of compound heterozygous SIL1 missense mutations causing
a neurological phenotype without signs of myopathy or
cataracts but including spastic paraplegia, thus not fulfilling
the clinical diagnostic criteria for MSS (10). Interestingly, the
number of detected SIL1 variants (n = 488; ExAC http://exac.
broadinstitute.org/) as of 11/2018 includes 147 missense and
7 non-sense variants with various effects on the phenotype.
Notably, these missense mutations also include the p.R92W
variant of SIL1, described as segregating with the phenotype
in a consanguineous family from Pakistan (11) but reported
in ExAC with an allele frequency of nearly 4% in south Asian
countries suggesting a polymorphic character. Given that (i)
the MSS phenotype can present with prominent additional
clinical features or characteristic features of the “clinical triad”
can be absent, (ii) missense mutations may have a detrimental
effect (10) and (iii) the detection of new SIL1 sequence
variants ever increasing in number, the need to classify the
pathogenicity is indicated. Here we introduce an in vitro system
designed to examine the consequences of SIL1 mutations at
the protein level, focussing on the stability of the variant SIL1
proteins, the morphology of cellular organelles, the build-up of
aggregated proteins, the activation of proteolysis and on the
SIL1-interactome. This procedure has allowed to differentiate
between benign and pathogenic variants (mostly due to amino
acid changes).
MATERIALS AND METHODS
Generation of SIL1-TAP and SIL1-HA
Expression Constructs
Using the SIL1-TAP expression construct (pcDNA5/FRT/TO
vector) (12) missense variants (listed below) as well as
one deletion variant of recombinant human SIL1 were
generated by site-directed mutagenesis. To this end, the
QuikChange Site-Directed Mutagenesis kit (Stratagene)
was used according to the manufacturer’s instructions.
Primer sequences are available on request. All constructs
were verified by sequencing the entire coding region of
the inserts.
The ORF of the human SIL1 cDNA was cloned in-frame
into the carboxy-terminal hemagglutinin (HA) tag containing
pRC/CMV expression vector. The same missense changes as
for the pcDNA5/FRT/TO vector systems were introduced by
site-directed mutagenesis using the QuikChange Site-Directed
Mutagenesis kit (Stratagene). Primer sequences are available on
request. All constructs were verified by sequencing the entire
coding region of the inserts.
The following SIL1 variants were selected and generated as
expression systems based on the following reasons:
p.R92W
A missense variant of ambiguous pathogenic character: reported
to cause MSS in a consanguineous Pakistani family (11) but
present in ExAC with an allele frequency of nearly 4% and
hereby also found to be homozygous in south Asian populations.
Evaluation of its pathogenicity was one aim of the present study
to address the suitability of our introduced in vitro system along
with different tests.
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p.K132Q
A missense variant of benign character (polymorphism) serving
as a control. which should give the same results as the wild-type
form of the SIL1 protein.
p.V231_I232del
A deletion variant with well-known pathogenicity based on
stability of the protein as described previously by immunoblot
and proteomics-based studies of MSS-patient-derived
immortalized lymphoblastoid cells (6, 13).
p.G312R
A missense variant of well-known pathogenicity based on
stability of the protein as described previously by immunoblot-
and proteomics-based studies of MSS-patient derived
immortalized lymphoblastoid cells (6, 13).
p.L457P
A missense variant with well-known pathogenicity in vitro
tested in COS7 cells and associated with clinical presentation of
MSS (14).
Cell Culture and Treatments:
Using the six pcDNA/FRT/TO-based expression constructs
for SIL1-TAP (wild-type and five variants), stable inducible
Hek293-TRex cell lines were generated as described previously
(12). Cells were cultured in Dulbecco’s Modified Eagle’s
medium (DMEM; Sigma-D5546) supplemented with 10 fetal
calf serum (FCS; Sigma- F2442). Transient transfection of
pRC/CMV-based constructs for SIL1-HA wildtype and variants
was performed utilizing Lipofectamine 2000 (Thermo Fisher
Scientific) according to the manufacturer’s instructions.
Immunoprecipitation of the SIL1 Variants:
As SIL1 can act as a dimer (5), the ability to form protein
dimers was addressed for the five protein variants of SIL1.
Dimerization of the wildtype-protein was examined as a positive
control to demonstrate functionality of the assay. The generated
stable inducible Hek293-TRex cell lines (grown on 10 cm dishes)
were additionally transfected with pRC/CMV-based constructs
for SIL1-HA wildtype and variants and were collected 8 h post-
transfection. Afterwards, cells were lysed in 500 µl of a buffer
containing 1mM EDTA (Sigma-Aldrich), 10% (v/v) glycerol
(Roth), 20mm HEPES (pH 7.5; Sigma-Aldrich), 150mM NaCl
(Sigma-Aldrich) and 0.8% (v/v) NP-40 (Roth) as well as 1 ×
Complete Protease Inhibitor Cocktail (Roche) for 1 h on ice.
Next, centrifugation (1.500 rpm) of the lysates was performed at
4◦C for 10min to separate the protein extracts from cell debris.
Protein concentrations were determined using the Pierce BCA
protein assay kit (Thermo Fisher) according to manufacturer’s
instructions. Immunoprecipitation of the different HA-tagged
forms of the SIL1 proteins via the TAP-tagged forms was
carried out as described previously (12) using 100 µg of total
protein extract.
For each experiment, cells overexpressing the solely the C-
terminal TAP-Tag were included to exclude unspecific binding
of the HA-Tagged versions of the SIL1 protein to the TAP-
tag. All co-immunoprecipitation experiments were carried out
three times.
Tandem-Affinity Purification of
SIL1-Interactome and LC-MS/MS-Based
Identification of Binding Partners
Interaction screening [tandem-affinity-purification (15) and
subsequent mass spectrometry] of SIL1 wildtype protein as
well as the five variant forms was carried out as described
previously (6, 12) For each experiment, three independent
biological replicates were analyzed.
Investigation of Cellular Fitness
Cellular fitness of Hek293-TRex cell lines overexpressing the
wildtype SIL1 protein as well as of cells overexpressing the five
variants was addressed by utilizing the WST-1 assay (Roche),
according to the manufacturer’s instructions. Cells treated with
H2O2 were included as a positive control of decreased cellular
fitness to demonstrate functionality of the assay. Moreover, cells
overexpressing the TAP-Tag only were included to demonstrate
that the presence/expression of the TAP-tag has no effect on
cellular fitness. The relative absorption in cells overexpressing the
SIL1 wildtype protein was considered as 100% of cellular fitness.
Native-PAGE, SDS-PAGE and
Western Blotting:
Native-PAGE was carried out as described in a protocol available
online (http://www.assay-protocol.com/molecular-biology/
electrophoresis/native-page) and the immunoblot studies were
performed as described previously (16). The following antibodies
were used:
Immunofluorescence:
Distribution of SIL1 wildtype protein as well as of the five
different variants was addressed in the stable inducible Hek293-
TRex cell lines: the respective cell lines (2 × 105 cells) were
plated onto 24-well plates on coverslips 12 h prior to induction
of expression with doxycycline as described before (12).
Beforehand, coverslips were coated with poly-L-lysine (Sigma-
Aldrich) for 1 h at room and afterwards washed twice with
ultra-pure water. Cells were fixed with 4% paraformaldehyde in
PBS pH 7.4 for 20min at room temperature. Afterwards, cells
were washed 3 times with ice-cold PBS. For permeabilization,
coverslips were incubated for 10min in PBS containing 0.25%
Triton X-100 (Roth). In the following step, cells were washed
in PBS 3 times for 5min. For blocking and immunostaining,
coverslips were incubated in 1% BSA (in PBS+ 0.1% Tween
20) for 45min and afterwards exposed to the anti-TAP antibody
(Sigma-Aldrich) 1:100 diluted in 1% BSA in PBST in a humidified
chamber overnight at 4◦C. Afterwards, coverslips were washed
3 times in PBS (5min each washing step) and then incubated
with the secondary antibody (goat anti-rabbit Alexa Fluor R©
568, Abcam) diluted 1:5,000 in 1% BSA-PBS for 1 h at room
temperature in the dark. Next, three washing steps times in PBS
(5min each washing step) were carried out. Finally, cells were
mounted with a drop of mounting medium (Thermo Fisher)
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and coverslips were sealed with nail polish to prevent drying and
movement under microscope. For analysis of immunoreactivity,
the Axiovert 200M microscope from Zeiss (240525) was used.
For each SIL1 variant as well as for the wildtype proteins 50
different cells were analyzed with more than 70% of cells giving
similar results, respectively.
For co-localization studies of SIL1, Hek293 cells were
permeabilized by incubation with 200 µL PBS buffer containing
0.1% Triton X-100 for 10min and subsequently washed
with PBS buffer. For blocking cells were incubated with
200 µL of PBS containing 0.1% TWEEN20 and 1% BSA
for 30min. Afterwards, cells were covered with 200 µL of
blocking solution containing the respective combinations of
both primary antibodies [α-CASQ1 (Sigma: C0618-200UL), α-
FAM134B (Genetex: GTX46621), α-POC1A (Thermo Fisher
Scientific: PA5-49028), α-SIL1 (Abcam: ab5639) dilution 1:300
each], incubated for 90min and then washed with PBS.
Secondary antibodies were diluted in 1% BSA (dilution 1:500 for
Alexa488 probe, 1:300 for Alexa555 probe). Cells were covered
with 200 µl of this antibody-solutions and incubated for 1 h in
the dark. Next, antibody solution was removed, and samples were
washed with BSA before the coverslips were directly mounted
with fluorescent mounting medium (“Prolong Gold antifade
reagent with DAPI” Invitrogen) and allowed to dry overnight
(at 6◦C). Fluorescence measurements were carried out with a
modified Leica TCS SP8 CARS laser scanning Microscope using
either a 20x objective (HC PL APO CS2 20x/0.75 DRY) or
a 63x objective (HC PL APO CS2 63x/1.20 WATER). Images
were acquired with a resolution of 2048 × 2048 pixel with a
step size of 286 nm for 20x magnification and of 91 nm for
63x magnification. Fluorescence measurements on each position
were performed sequentially using laser excitation at 488 nm
and detection at 500–540 nm with a hybrid detector (LeicaHyD),
excitation at 561 nm and detection at 566–620 nm with a HyD
and excitation at 405 nm with detection at 425–500 nm using a
PMT. All data processing was carried out using Matlab R2015a.
Due to variations in fluorescence intensity between the samples
as well as between the different dyes data were preprocessed for
better comparability. To reduce background, noise data points
having < 2% of intensity were set to this lower threshold value.
To account for cosmic spikes, the upper threshold was set so
that a maximum of 0.1% of all data points above background
showed fluorescence intensity above this limit. Intensities above
the upper threshold were set to this value. Images were then
rescaled to full range (8bit). For calculation of co-localization
values in each channel, all data points exceeding an intensity
value of 20% were determined. Data points that are above this
value in both channels were considered to be co-localizing.
The ratio of co-localization is calculated from the number of
co-localizing points divided.
Electron Microscopy
Preparation of Hek293-TRex cell lines and subsequent
transmission electron microscopic studies were carried out
as described previously (12, 16). For each SIL1 variant as well as
for the wildtype protein, at least 50 cells were analyzed showing
similar (patho)morphology of subcellular organelles/structures.
RESULTS
Literature and in silico-Based Evaluation of
the Pathogenicity of Selected SIL1-Variants
We chose one known polymorphism (p.K132Q), three
notoriously pathogenic mutations (p.V231_I232del, p.G312R,
and p.L457P) and p.R92W, a variant that was previously
described as a pathogenic missense mutation (11). Notably, the
two missense variants pR92W and p.K132Q are present in the
control population with minor allele frequencies (MAF) of 0.5
and 0.7%, respectively, and in 29 and 72 healthy individuals
in homozygous state. On the other hand, p.G312R is absent
from a control population of >125,000 individuals (ExaC,
http://exac.broadinstitute.org) and p.L457P is found in one
allele count (MAF: 0.0004%) (http://gnomad.broadinstitute.
org). The sites of the different variants/ mutations are depicted
in Figure 1A. By affecting α-helix A8 of the SIL1-protein, the
p.V231_I232del mutation directly impacts on the physiological
SIL1-BiP interaction lobe IIb of the BiP-ATPase domain (major
interaction site). Although the polymorphic variant p.K132Q
and the reported pathogenic missense mutant p.G312R are
also localized within the SIL1-BiP-binding domain, they do not
directly affect α-helices mediating the physical interaction with
BiP. The ambiguous missense variant, p.R92W, localizes within
the N-terminal domain of the 461 amino acid SIL1 protein
and p.L457P, another known pathogenic missense mutant of
SIL1 affects one amino acid localized before the known ER-
retention motif KDEL/KELR (17) (Figure 1A). Interestingly, in
silico testing of pathogenicity with different platforms revealed
controversial results including a probably damaging effect for
all amino acid substitutions addressed in this study (Figure 1B).
This result is in contrast with the observed allele frequencies
in the control population and by the same token emphasizes
the need to define biomarkers that can be used to evaluate
the pathogenicity of SIL1 mutations—in particular of amino
acid substitutions.
Molecular Characteristics of Selected
SIL1-Variants in a Non-reducing PAGE
First, molecular characteristics of the selected SIL1-variants were
addressed in a non-reducing PAGE (and concomitant blotting to
a PVDF-membrane) utilizing whole protein extracts. Detection
of the different variant forms of the recombinant SIL1-protein
utilizing an anti-SIL1 antibody (see Table 1) revealed no major
differences in the detected molecular weight of wildtype SIL1-
TAP in comparison to the ambiguous p.R92W and the benign
p.K132Q variants of SIL1. In contrast, no band was detectable for
p.V231_I232del-mutant SIL1 (16 h of induced overexpression)
suggesting instability of the aberrant protein, a finding which is
in line with our previous studies on patient derived cells (6, 12).
However, absence of this mutant form of the protein might
also arise from a changed antigenicity of this variant product.
Immunoblots of the two well-known pathogenic mutant forms,
p.G312R and p.L457P, did not only show protein bands of the
predicted size of the recombinant fusion-protein (SIL1-TAP) but
also additional bands corresponding to a highermolecular weight
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FIGURE 1 | Overview of investigated amino acid changes of SIL1. (A) Localization of SIL1 amino acid changes in the entire SIL1 protein. Schematic figure is modified
from Yan et al. (5). (B) Table summarizing the SIL1 variants by providing information regarding the corresponding nucleotide change/ deletion in different exons within
the SIL1 gene as well as origin of the respective MSS-patient and results of in silico-based testing of pathogenicity by “CADD score” and “ClinVar” as well as by
“SIFT“, “PluPhen2“, “MutationTaster“ and “FATHMM” (summarized as in silico prediction). D, damagingl; P, pathogenic; B, benign; T, tolerated.
which appear to be more pronounced for p.G312R (Figure 2A).
The experiment was performed 6 times with similar results.
Influence of Amino Acid
Substitutions/Deletions
on SIL1-SIL1-Interactions:
Given that SIL1 can act as a dimer (6), we addressed the
effect of the various amino acid changes and of the deletion of
two amino acids (p.V231_I232del) on the formation of SIL1-
protein homomers by immunoprecipitation and subsequent
immunoblot analyses. As a proof-of-principle, the well-known
homomerization of SIL1 wild-type proteins was confirmed
(Figure 2B). Both, the ambiguous p.R92W and the benign
p.K132Q variants showed a homomerization similar to the
one observed for the wild-type SIL1-TAP-SIL1-HA complex
(Figures 2C,D). Analyses of the well-known pathogenic
p.V231_I232del mutation revealed no interaction of the
resulting degradation products in terms of the formation of
toxic (proteolytic) protein complexes (Figure 2E). Study of the
two-known pathogenic SIL1-proteins, p.G312R and p.L457P,
showed that they can form homomeric complexes along with
their degradation products (Figures 2F,G). Immunoblot-based
analyses of whole protein extracts/ straight lysates confirmed
the expression of the respective recombinant SIL1-variants
tagged with HA or TAP in each of the respective experiments.
All immunoprecipitation and immunoblot experiments were
performed three times with similar results.
Influence of Amino Acid Substitutions/
Deletions on the Fitness of the in vitro
Models
Mitochondrial vulnerability has been repeatedly reported in
MSS and woozy mouse tissues (13, 18–20), and in in vitro
models of the disease (13, 16). As mitochondrial function is
essential for cellular fitness, we examined metabolic activity
of our in vitro models by focussing on processes related to
mitochondrial activity as well as on mitochondrial morphology.
The WST-1 assay (Roche) was used; in this assay the stable
tetrazolium salt, WST-1, is cleaved to a soluble formazan. This
conversion depends on the cellular availability of succinate-
tetrazolium reductase system that belongs to the respiratory
chain of the mitochondria (only active in metabolically intact
cells). Thus, the amount of formazan dye formed directly
correlates to the number of metabolically intact cells in the
culture. Metabolic activity in WT-SIL1 cells was defined as
100% of cellular fitness. The WST-1 assay revealed no reduction
in metabolic activity upon overexpression of the ambiguous
p.R92W or of the benign p.K231Q variant of SIL1 (Figure 3A).
Overexpression of the p.V231_I232del mutant form of the SIL1-
protein (which displayed instability in our previous experiment,
see above) resulted in a minor but significant decrease of the
fitness (Figure 3A). In contrast, overexpression of the known
pathogenic mutants p.G312R and p.L457P led to a 15–20%
reduction in cellular viability compared to cells overexpressing
the WT-SIL1 (or solely the TAP-Tag) suggesting an effect of
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TABLE 1 | All immunoblot studies were carried out at least three times.
Antibody Company Dilution
α-Beclin Novus Biologicals: NB110-87318 1:1000
α-CBP Thermo Fisher Scientific: PA1-847 1:1000
α-CHOP Novus Biologicals: NB600-1335SS 1:500
α-DJ-1 Santa Cruz: sc-55572 1:750
α-DNAJB6 Genetex: GTX33160 1:500
α-ERj3 Novus Biologicals: NBP1-68477 1:500
α-FAM134B Genetex: GTX46621 1:500
α-GAPDH Genetex: GTX627408 1:1000
α-GRP94 Genetex: GTX103203 1:1000
α-GRP170 Genetex: GTX102255 1:1000
α-HA Sigma Aldrich: H3663-100UL 1:500
α-IRE1 Genetex: GTX130387 1:500
α-pEif2α (Ser52) Thermo Fisher Scientific: 44-728G 1:1000
α-PERK Abcam: ab65142 1:500
α-POC1A Thermo Fisher Scientific: PA5-49028 1:500
α-SIL1 Abcam: ab5639 1:100
α-SOD1 Genetex: GTX100554 1:1000
α-VCP Genetex: GTX101089 1:1000
List of antibodies used in the study.
their pathogenicity on cellular metabolism (Figure 3A). H2O2-
treated Hek293 cells were included as a positive control for
perturbed mitochondrial function based on massive oxidative
stress burden (Figure 3A). The assay was carried out 4 times
with similar results. Given thatmitochondrial vulnerabilitymight
be connected to oxidative stress, a well-known epiphenomenon
of ER-stress, levels of DJ1 and SOD1 (two proteins known
to be modulated by oxidative stress burden) were studied by
immunoblotting. Hek293 cells overexpressing the pathogenic
missense variants of SIL1, p.G312R, and p.L457P, showed
an increase in DJ1 (lower band), with a more pronounced
effect in cells overexpressing p.G312R mutant SIL1. Cells
overexpressing p.G312R mutant SIL1 showed a considerable
increase in SOD1 protein, whereas there was no difference
between the cells overexpressing the wildtype protein and those
overexpressing the pathogenic p.L457P variant (Figure 3B).
However, the increase of SOD1 in Hek293 cells overexpressing
p.V231_I232del mutant form was comparable to the SOD1
increase in cells overexpressing the benign p.K132Q variant
(Figure 3B. Notably, a parallel “trend” of abundances of DJ1
and SOD1 expression changes modulated by SIL1 variants can
be observed. Prompted by the results of the WST-1 assay
and by the immunoblot studies, mitochondrial-morphology
was examined by electron microscopy. EM revealed normal
ultrastructure of Hek293 cells overexpressing wild-type SIL1 as
well as p.R92W- and p.K132Q variant forms of the SIL1 protein
(Figure 3C). In contrast, Hek293 cells overexpressing the known
pathogenic SIL1-missense mutations, p.G312R and p.L457P,
presented with perturbed mitochondrial architecture including
break-down of cristae and accumulation of electron-dense
membranous material in the mitochondrial matrix most likely
indicative of incipient mitophagy/ mitoptosis (21) (Figure 3C).
Overexpression of the pathogenic but instable p.V231_I232del
mutant form did not result in such a profound mitochondrial
pathology. This might actually be due to the higher stability of the
pathogenic missense mutant forms of SIL1 resulting in persistent
mitochondrial stress. Pathomorphological mitochondria could
be detected in 41 of 50 cells (82%) expressing the p.L457P and in
38 of 50 cells (76%) expressing the p.G312Rmutant formwhereas
in cells expressing wildtype SIL1 or the variants p.R92W and
p.K132Q, pathomorphological mitochondria were found in 10%,
18% and 14%, respectively (50 cells were analyzed for each in vitro
model). Only 12% of Hek293 cells overexpressing the pathogenic
but instable p.V231_I232del mutant displayed morphological
aberrant mitochondria.
Pattern of Cellular SIL1
Staining—Polymorphic vs. Pathogenic
Forms of the Protein:
Immunofluorescence studies of our Hek293 in vitro models
overexpressing the different forms of the SIL1 protein in an
inducible fashion were performed to address the question if
the pattern of SIL1-TAP-immunoreactivity allows to differentiate
between polymorphic variants and pathogenic mutations.
Indeed, cells overexpressing WT-SIL1 in comparison to those
overexpressing the two known pathogenic missense forms
(p.G312R and p.L457P) showed significant differences regarding
the pattern of immunoreactivity. WT-SIL1 was distributed
in a reticular network in accordance with a regular ER-
localization, whereas p.G312R- and p.L457Pmutant SIL1 showed
an altered non-reticular immunoreactivity pattern (Figure 4A).
In contrast, p.V231_I232del mutant SIL1 (after 6 h of induced
overexpression) showed a reticular distribution comparable to
WT-SIL1 and the polymorphic p.K132Q form but with some
focal accumulations (Figure 4A). Notably, immunoreactivity
of p.R92W variant SIL1 does not show the same subcellular
distribution as the p.G312R and p.L457P mutants and rather
presents as a reticular network as observed for WT-SIL1 and
p.K132Q but with some minor focal accumulations.
Influence of Amino Acid
Substitutions/Deletions on ER-Morphology
and Function in our in vitro Models
To follow up on the immunofluorescence studies described
above, EM was performed. ER in Hek293 cells overexpressing
WT-, p.R92W and p.K132Q versions of SIL1 showed a
regular tubular structure. In cells overexpressing p.G312R
and p.L457P mutant SIL1, the ER showed focal widening,
occasionally associated with accumulation of electron dense
material most likely corresponding to protein aggregates within
the widened ER (black arrows in Figure 4B). In addition, cells
overexpressing these two known-pathogenic mutants exhibited
autophagic vacuoles that were often filled with membranous
and granular osmophilic material (Figure 4B). Deposits of
osmophilic material (mostly localized to autophagic vacuoles)
were also detected in Hek293 cells with short-term (6 h)
overexpression of p.V231_I232del mutant SIL1 (Figure 4B).
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FIGURE 2 | Impact of amino acid substitutions and deletions on the molecular characteristics of SIL1. (A) Native-PAGE of SIL1 variants reveals absence of
p.V231_I232del mutant SIL1 (16 h of induced overexpression) but no differences in the migration pattern of the different missense variants of SIL1. The two known
pathogenic variants p.G312R- and p.L457P present additional bands of a higher molecular weight. (B–G) Immunoprecipitation and subsequent immunoblot analysis
toward the study of SIL1-homomerization confirmed the known SIL1-SIL1 interaction of the wildtype form of the protein (B) and showed no effect of the p.R92W- or
p.K132Q-amino acid substitutions on this interaction (C,D). Study of p.V231_I232del mutant SIL1 (6 h of induced overexpression) did not show a physical interaction
of the degradation products of this known pathogenic and instable form of SIL1 (E). Analysis of the two known missense mutants p.G312R- and p.L457P revealed in
both cases a homomerization of the full-length mutant proteins but also an interaction of the mutant full-length protein with the respective degradation products (F,G).
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FIGURE 3 | Study of fitness of Hek293 cells overexpressing SIL1 or its variant forms in the context of mitochondrial vulnerability. (A) ELISA-based WST-1 assay
showed a statistically significant reduction in the fitness of cells overexpressing the known pathogenic variants p.V231_I232del (6 h of induced overexpression),
p.G312R and p.L457P, respectively. In accordance with the instability of p.V231_I232del mutant SIL1, the fitness is more reduced in Hek293 cells overexpressing
p.G312R and p.L457P mutant forms of SIL1. Hek293 cells treated with H2O2 were included as positive control showing the functionality of the assay. (B)
Immunoblot-based studies of DJ1 (lower band) and SOD1 as two representative marker proteins for oxidative stress (related to mitochondria) showed a considerable
increase of DJ1 in cells overexpressing p.G312R or p.L457P mutant SIL1. Surprisingly, SOD1 was only markedly increased in cells overexpressing p.G312R mutant
SIL1, but not in cells overexpressing p.L457P mutant SIL1. GAPDH was used to demonstrate equal protein loading. (C) EM revealed normal mitochondrial
architecture in Hek293 cells overexpressing WT-SIL1, p.R92W and p.K132Q variant SIL1 as well as p.V231_I232del mutant SIL1 but disintegration of cristae and
presence of membranous electron-dense material within the mitochondrial matrix (black arrows) in cells overexpressing the two known pathogenic missense variants
p.G312R and p.L457P. **Statistically very significant; ***Statistically extremely significant.
Prompted by our ultra-structural findings, we next
investigated the presence of ER-stress upon overexpression
of wildtype SIL1 as well as the 5 different variants at the
molecular level by immunoblotting by focussing on the
abundances of 10 proteins modulating the unfolded protein
response (UPR) and the ER-associated degradation pathway
(ERAD). In accordance with our previous published data
(12), overexpression of wildtype SIL1 results in the increased
expression of these factors compared to cells overexpressing
solely the TAP-Tag (Figure 4C). This in turn also explains
the altered expression of these factors in Hek293 cells with
long-term overexpression of the instable p.V231_I232del mutant
form. However, overexpression of neither the polymorphic
p.K132Q nor of the ambiguous p.R92W variant led to a
sustained increase of the UPR-/ ERAD-related proteins
compared to cells overexpressing the wildtype form of SIL1
(Figure 4C). Overexpression of p.G312R resulted in an
increased expression of GRP170 and Beclin-1 as well as forced
phosphorylation of eIF2α compared to cells overexpressing
the TAP-tag only, the wildtype variant of SIL1 or the
p.R29W and p.K132Q variants, respectively (Figure 4C).
The overexpression of p.L457P mutant SIL1 even resulted in
elevated abundance of all investigated UPR-/ ERAD-proteins
except HSP40/ ERj3 (Figure 4C).
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FIGURE 4 | Study of cellular SIL1 immunoreactivity and presence of ER-stress in Hek293 cells overexpressing SIL1 or its variant forms. (A)
Immunofluorescence-based investigation of the SIL1-immunoreactivity pattern in Hek293 cell revealed a reticular distribution for WT-SIL1, p.R92W and p.K132Q
variant forms of SIL1 but a non-reticular rather “clumpy” immunoreactivity for p.G312R and p.L457P mutant forms of SIL1. For p.V231_I232del mutant SIL1, a
reticular distribution with focal accumulations was observed. (B) EM revealed widened and proliferated ER in cells overexpressing the mutant forms p.G312R and
p.L457P, but not in cells overexpressing WT-SIL1, p.R92W, p.K132Q, and p.V231_I232del (6 h of induced overexpression) forms of the proteins. In addition,
accumulation of electron dense material could occasionally be seen in cells overexpressing p.G312R and p.L457P muatnt SIL1 (black arrows). Along this line,
(Continued)
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FIGURE 4 | overexpression of these two known missense mutants of SIL1 resulted in the build-up of electron dense material (most likely corresponding to
aggregated protein) in the cytoplasm as well as in (autophagic) vacuoles. The white arrow highlights an abnormal centrosome in a Hek293 cell overexpressing
p.G312R mutant SIL1. (C) Immunoblot-based studies aimed to investigate the presence of ER-Stress by focussing on marker proteins for activation of the unfolded
protein response (GRP170, IRE1, PERK, GRP94, ERj3 & pEif2α), the ER-associated degradation pathway (VCP, DNAJB6) and proteolysis (Beclin). Results revealed a
considerable presence of ER-stress in Hek293 cells overexpressing p.L457P mutant SIL1 than in cells overexpressing p.G312R mutant SIL1 where solely pEif2α and
Beclin are increased compared to cells overexpressing WT-SIL1. p.R92W, p.K132Q variant SIL1, and p.V231_I232del mutant SIL1 (6 h of induced overexpression) do
not show remarkable changes in abundances of the stress markers compared to cells overexpressing WT-SIL1. GAPDH was investigated to demonstrate equal
protein loading. The differences in expression of these markers between C-TAP and WT-SIL1 overexpressing Hek293 cells have been described previously (12).
Influence of Amino Acid
Substitutions/Deletions on
SIL1-Protein-Binding and Subsequent
Morphological Effects in our in
vitro Models
To define another read-out measure enabling the robust
evaluation of the pathogenicity of amino acid changes and
deletions in SIL1, tandem-affinity-purification followed by mass
spectrometric analysis of the different TAP-tagged variants of the
SIL1 protein was performed. Overexpression of p.V231_I232del
mutant SIL1 was induced by doxycycline treatment for 6 h
to study binding partners prior degradation of this instable
pathogenic SIL1 protein. Results of this screening approach
are presented in Figure 5A and show that all variants of the
SIL1-protein bind to BiP, Mortalin and the small subunit of
Calpain-1. Moreover, our protein-interaction studies revealed a
precipitation of ERj3 along with the two pathogenic mutants
of SIL1, p.G312R, and p.L457P, but not with the two variants
p.R92W and p.K132Q or the wildtype form of SIL1. Remarkably,
our unbiased studies focusing on interaction of different forms
of SIL1 to other proteins revealed that the wildtype protein
as well as the p.R92W and p.K132Q variants are precipitating
with POC1A whereas immunoprecipitation of p.G312R and
p.L457Pmutant SIL1 along with their interactors and subsequent
mass spectrometry studies did not result in the identification
of POC1A as a binding partner. Given that mutations in
POC1A are causative for SOFT (short stature, onychodysplasia,
facial dysmorphism, and hypotrichosis) syndrome (22) and
short stature is also a clinical finding in MSS patients, a
regulatory effect of abundances of the SIL1-wildtype protein
on level of POC1A was confirmed by immunoblot studies.
Our findings highlight an effect of cellular SIL1 level on
POC1A protein abundance (Figure 5B, left). POC1A encodes
for a protein linking centrosomes to Golgi assembly and
function, and recessive mutations affecting this gene result in
perturbed Golgi structures and cytosolic vesicle accumulations,
in addition to abnormal multipolar spindles in vitro (22, 23).
This known POC1A function along the mentioned pathological
findings resulting from mutations in the corresponding gene
prompted us to also study the level of FAM134B, a newly
identified cis-Golgi protein with a pivotal role in neuronal
function and survival (24) in relation to the expression of
SIL1 wildtype protein as well as the morphology of Golgi
and centrosomes. Indeed, immunoblot studies of FAM134B
showed a beneficial effect of SIL1 expression on the abundance
of this Golgi-protein (Figure 5B, left). Results of expression
studies in Hek293 cells expressing different mutant forms of
the protein show a clear influence of the pathogenicity of SIL1-
mutations on the abundance of the FAM134B and POC1A
proteins (Figure 5B, right).
Prompted by our SIL1-protein interaction findings suggestive
for a localization of SIL1 also to the Golgi-apparatus, further
immunofluorescence studies have been performed and revealed
an expected co-localization of SIL1 with calsequestrin (CASQ1;
a known ER-marker protein) and additionally co-localizations
with golgin-97 (a known marker protein of the Golgi apparatus)
as well as with FAM134B and POC1A. Quantification of these co-
localizations revealed that the excessive proportion of the SIL1
protein localizes to the ER but almost equal co-localization with
golgin-97, FAM134B and POC1A indicates a minor localization
of SIL1 also within the Golgi apparatus (Figure 5C).
Results of further ultra-morphological studies focussing on
the integrity of Golgi and centrosomes revealed proliferated
and dispersed Golgi cisternae in Hek293 cells overexpressing
p.G312R or p.L457P but not in cells overexpressing the
wildtype form of the protein (Figure 5D). Whereas, neither the
polymorphic p.K132Q nor the ambiguous p.R92W variant of
SIL1 presented with changes in Golgi architecture compared
to cells overexpressing WT-SIL1 (data not shown), Hek293
cells with short-term overexpression of p.V231_I232del showed
only a very mild widening of Golgi cisternae (Figure 5D).
Interestingly, altered Golgi structures could frequently be
detected adjacent to abnormal centrosomes as exemplified for
p.V231_I232del and p.G312R in Figure 5D (black arrows). Along
this line, overexpression of the pathogenic forms of the SIL1
protein in Hek293 cells repeatedly resulted in disintegration
of centrosome architecture including centriole-multiplications
and -proliferations as well as mis-localization of centrioles to
lysosomes and vacuoles (Figure 5E).
DISCUSSION
On a general note, the need of suitable in vitro systems allowing a
reliable testing of ambiguous gene mutations potentially affecting
stability and localization of the corresponding protein is crucial
in the cases that patient-derived tissue is not available to
perform verification studies. Here, using MSS as a paradigmatic
rare neurogenetic disease, we demonstrate that Hek293 cells
overexpressing different mutant forms of the SIL1 protein are
suitable to evaluate the pathogenicity of SIL1 mutations such as
missense variants and in-frame-amino acid deletions. MSS has
been selected for our studies as:
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FIGURE 5 | Study of SIL1-interactome and impact of interaction on subcellular morphologies. (A) Table presenting SIL1-protein interactions identified by
tandem-affinity-purification and subsequent mass spectrometry in an unbiased fashion: whereas WT-SIL1 and its (polymorphic and pathogenic) variants interact with
BiP, Mortalin and the small subunit of Calpain-1, solely WT-SIL1, p.R92W and p.K132Q variant forms of SIL1 precipitated POC1A. In contrast, solely p.G312R and
p.L457P mutant SIL1 precipitated ERj3, a known BiP-binding protein controlled by ER-stress. the detection of SIL1—as shown in the table presented—refers to the
identification/ detection of tryptic peptides unique for the SIL1 protein in the mass spectrometric analysis. The peptides identified for the respective SIL1-variant arise
from the overexpression of same ones and show the reliability of the combined IP-LC-MS/MS data. (B) Immunoblot-based study of FAM134B and POC1A revealed
increased expression of both proteins upon elevation of the cellular SIL1 level. Coomassie-staining was carried out to demonstrate equal protein loading (left panel).
Results of expression studies in Hek293 cells expressing different mutant forms of the protein show a clear influence of the pathogenicity of SIL1-mutations on the
abundance of the FAM134B and POC1A proteins (right panel). (C) Results of our co-immunofluorescence studies focussing on SIL1 localizations revealed
co-localizations of SIL1 with CASQ1 (calsequestrin), golgin-97, FAM134B, and POC1A. Representative overviews of cells are shown for each respective
co-localization study which have also been used for the quantifications of co-localizations (right diagram). (D) EM of Golgi morphology revealed a regular architecture
in Hek293 cells overexpressing WT-SIL1, but proliferated and dispersed Golgi with widened terminal cisternae (white arrows) and vesicle accumulations in cells
overexpressing p.G312R or p.L457P mutant SIL1. In cells overexpressing p.V231_I232del mutant SIL1, solely a mild pathology of the Golgi apparatus (widened
cisternae indicated by white arrows) could be observed. (E) EM of centrosome morphology revealed a regular architecture in Hek293 cells overexpressing WT-SIL1,
but proliferated, multiplicated and dispersed centrosomes in cells overexpressing the pathogenic missense mutant pG312R or p.L457P (black arrows). Remarkably, in
cells overexpressing these two known pathogenic forms of SIL1, a mis-localization of abnormal centrosomes to lysosomes (black arrows in pictures 2 and 4) or to
vacuoles (black arrow in the inset of picture for as well as in picture 5) was observed.
• The phenotype can present with prominent additional clinical
features or characteristic features of the “clinical triad” can be
absent thus complicating the evaluation of detected variants in
terms of phenotype-causative mutations
• Missense mutations may have a detrimental effect on the
clinical presentation (10)
• Detection of new SIL1 sequence variants is ever
increasing in number thus indicating the need to classify
their pathogenicity.
Indeed, the combination of different biochemical,
morphological and functional studies utilizing Hek293 cells
overexpressing different variants of SIL1 of known and
ambiguous pathogenicity allowed to introduce a system enabling
the in vitro-based evaluation of SIL1 variants leading to amino
acid substitutions or deletions: results of our SIL1-protein studies
in a non-reducing PAGE suggest that although the pathogenic
variants do not cause essential changes in the behavior of the
main SIL1 band, bands of higher molecular weight occur which
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most likely correspond to aberrant SIL1 protein complexes.
The absence of these bands under reducing conditions (data
not shown) indicates that these aberrant complexes are soluble.
Hence, the presence of additional (higher molecular weight)
SIL1 bands in a non-reducing PAGE might serve as a read-out
measure to evaluate the pathogenicity of amino acid substitutions
in SIL1. The absence of these bands in immunoblots of WT-SIL1,
p.K132Q and p.R92W variants of SIL1 suggest that p.R92W is a
benign variant rather than a pathogenic mutation.
In addition, studies focussing on the influence of amino acid
substitutions/ deletions on SIL1-SIL1-interactions provided a
new outcomemeasure toward the evaluation of the pathogenicity
of SIL1 variants: given that degradation products of the
p.V231_I232del, the p.G312R and the p.L457P mutant forms
of SIL1 can be identified utilizing the straight protein lysates
of the SIL1-SIL1 interaction experiment and anti-HA/TAP
antibodies (detecting the respective Tags at the C-terminus of
the recombinant proteins) a N-terminal initiated degradation
of these mutant forms of the protein is suggested. The
presence of degradation products for p.G312R and p.L457P
mutant SIL1 (Figures 2F,G) in combination with the detected
higher molecular weight bands for these forms as presented
in Figure 2A suggests formation of protein aggregates and
breakdown. A comparison of the degradation of the variant
forms of SIL1 with known pathogenic character suggests a
much higher instability of SIL1 exhibiting deletion of two amino
acids compared to the two forms with C-terminal substitutions.
Taken together, this assay shows that precipitation of degradation
products might be indicative for a pathogenic character of amino
acid changes in SIL1.
Given that mitochondria display a considerable vulnerability
in the etiology of MSS (13, 18–20), WST-1 assay has been
performed to investigate mitochondrial activity in our MSS in
vitromodels and results suggest a benign character of the p.R92W
and p.K132Q amino acid changes in SIL1 whereas the pathogenic
character of the p.G312R and p.L457P missense mutants could
be confirmed. The mild reduction of the cellular fitness in
cells overexpressing the instable p.V231_I232del mutant form
of SIL1 (while cells still also express the endogenous SIL1
protein) might arise from impairment of cellular processes until
degradation of the mutant recombinant protein is fully achieved.
Findings of this assay suggest a reduced metabolic activity as a
cellular biomarker or read-out measure of pathogenicity of SIL1
mutations. As the expression of pathogenic SIL1 variants also
impacts on morphological integrity of mitochondria, presence
of oxidative stress and perturbed mitochondrial architecture
might represent further useful read-out measures for the in vitro
evaluation of pathogenicity of overexpressed SIL1 mutations
that are associated with a loss of function rather than a loss of
protein. However, the less pronounced oxidative stress burden in
the case of overexpression of p.L457P mutant SIL1 (Figure 3B)
suggests that analysis of oxidative stress should not serve as
a mere measure to evaluate the pathogenic character of SIL1
missense variants.
To address cellular SIL1 immunoreactivity and distribution as
a further measure to evaluate pathogenicity of SIL1 amino acid
substitutions and deletions immunofluorescence studies have
been carried out and -in comparison to the Hek293 cells over
expressing the SIL1 wildtype protein—altered immunoreactivity
could be observed for p.G312R and p.L457P and to a minor
degree for p.V231_I232del overexpressing cells but not for
cells overexpressing p.R92W or p.K132Q variants of SIL1.
As a pathomorphological immunoreactivity-pattern has already
been demonstrated for p.L457P mutant SIL1 in COS7 cells
(14), the recapitulation in Hek293 cells confirms the suitability
of these cells to investigate pathogenicity of SIL1 mutations.
Moreover, a similar pattern of immunoreactivity has been
shown in vitro upon overexpression of a pathogenic form
of SIL1 caused by a deletion of thymidine at base-pair
position 1366 of the corresponding gene (17). Consequently,
our immunofluorescence findings confirm the pathogenicity
of p.G312R mutant SIL1. One might speculate that the small
focal accumulations of the p.V231_I232del mutant form of SIL1
represent early stages of degradation of the mutant protein, an
assumption that is in line with the detection of degradation bands
upon short-term overexpression (Figure 2B) and the absence
of the protein upon long-term overexpression (Figure 2A).
As immunofluorescence studies of p.R29W did not reveal
pathological changes compared to the cells overexpressing the
wildtype or the p.K132Q variant form of SIL1, the combined
results support the notion that p.R92W is a polymorphic variant
rather than a pathogenic mutation and also indicate that the
pattern of SIL1 immunoreactivity might serve as another cellular
biomarker or read-out measure allowing the evaluation of
pathogenicity of SIL1 amino acid substitutions.
The altered distribution and aggregation of p.G312R and
p.L457P mutant forms of SIL1 prompted us to focus on
subcellular ultrastructural alterations suggestive for protein
aggregation and proteolysis. Indeed, electronmicroscopic studies
revealed the presence of vacuoles in Hek293 cells overexpressing
these two pathogenic missense variants of SIL1. One might
assume that these vacuoles result from impaired ER-function and
thus protein processing resulting in accumulation of osmophilic
material which could also be observed in the cytoplasm (not
localized within vacuoles; white arrows in Figure 4B). As
the p.V231_I232del pathogenic mutation is instable, protein
aggregates and vacuoles identified by electron microscopy might
correlate to the degradation of the mutant SIL1 protein.
Importantly, build-up of electron-dense aggregates and altered
ER morphology have also been described in immortalized
lymphoblastoid cells from patients [including heterozygosity for
p.V231_I232del and p.G312R, (6, 13)] as well as in Hek293
cells with depleted SIL1 expression (16) but also in MSS-
patient derived fibroblasts (25). This in turn confirms the
suitability of our generated in vitro overexpression models to
evaluate the pathogenicity of SIL1 mutations on the ultra-
structural level. However, results of our immunoblot-studies
focussing on ER-stress and activation of proteolysis suggested
a more profound ER-vulnerability and proteolytic activation in
Hek293 cells overexpressing the p.L457P-mutant form of SIL1
and furthermore again suggest that the p.R92W is in fact a
polymorphic missense variant of SIL1. Based on the relatively low
effect of the overexpression of p.G312R (showing a detrimental
effect on oxidative homeostasis; see above) on ER-homeostasis
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and proteolysis compared to overexpression of p.L457P, the
necessity of parallel investigations of different read-out measures
to draw a meaningful conclusion regarding the pathogenicity of
SIL1 variants is indicated.
SIL1-interactome has been addressed as a potential further
measure to evaluate the pathogenicity of amino acid changes
in SIL1 and results showed that all variants of the SIL1-protein
investigated in this study bind to BiP, Mortalin and the small
subunit of Calpain-1. In this context it is important to note that
an ER localization of Mortalin which shows a high homology to
BiP has already been described (26). Given that Calpain-1 acts
as a non-lysosomal thiol-protease catalyzing proteolytic cleavage
of substrate proteins, its binding to all five variants of SIL1 as
well as toWT-SIL1 might result from protein overexpression and
serves toward the elimination of excessive level, an assumption
supported by our previous findings in Hek293 cells with WT-
SIL1 overexpression (12). As BiP represents a well-known
binding partner of SIL1 but also acts as a major chaperone
in the UPR facilitating the re-folding of misshaped proteins,
it is difficult to evaluate whether the interaction of BiP with
the different variants of SIL1 is physiological or a result of an
attempt to warrant a native folding of the protein in case of the
binding to the pathogenic forms of SIL1. Notably, localization
of p.V231_I232del- and p.G312R-amino acid changes in the BiP-
binding domain of SIL1 (Figure 1A) are suggestive for a binding
of BiP to these SIL1-forms (or degradation products) toward
re-folding and antagonization of build-up of (toxic) protein
aggregates. This hypothesis is further supported by the fact that
DNAJB11/ERj3 serves as another BiP co-chaperone (stimulating
ATPase activity) by direct binding to both unfolded ERAD-
substrates and nascent unfolded peptides, but dissociates from
the BiP-unfolded protein complex before folding is completed
(27) and our molecular observation of ERj3 binding to p.G312R
and p.L457P mutant SIL1 but not to WT-SIL1, and the
p.R92W and p.K132Q variants. Thus, it seems plausible that
the functional ERj3-BiP complex is recruited to the pathogenic
missense variants based on pathophysiological circumstances.
On a general note, this finding moreover suggests that ERj3
binding to SIL1 or rather the SIL1-BiP complex might serve as
a molecular measure/ biomarker to evaluate the pathogenicity
of stable SIL1 missense variants. However, results of our
immunoblot studies of ER-stress related proteins did not show
elevated ERj3 level in Hek293 cells overexpressing p.G312R and
p.L457Pmutant SIL1 compared cells overexpressing the wildtype
SIL1 protein (Figure 4C) indicating that cellular available ERj3
pools are re-located to the two pathogenic mutant forms of
SIL1. Mass spectrometry-based analysis of SIL1-interacotme
moreover revealed that the wildtype protein as well as the
p.R92W and p.K132Q variants bind to POC1A. Interestingly,
immunoprecipitation of the p.G312R and p.L457P forms of SIL1
along with their interactors did not result in the identification
of the binding to POC1A. This finding defines the interaction
of POC1A with SIL1 variants as further read-out measure
to evaluate the pathogenicity of amino acid substitutions and
deletions in SIL1 and by the same token underlines our previous
findings suggesting that the p.R92W variant form of SIL1
is in fact a polymorphic variant rather than a pathogenic
TABLE 2 | Overview of cellular markers and respective analytical approaches
toward evaluation of pathogenicity of SIL1-mutants.
Test Cellular marker of pathogenicity
Native and reducing PAGE with
subsequent Western-Blot of
SIL1 protein
Higher and lower molecular weight bands as
signs of protein aggregates (in native PAGE)
and degradation products
WST-1 viability assay Reduced viability
Immunofluorescence of
SIL1-protein
Non-reticular pattern of immunoreactivity
Electron microscopy Abnormal mitochondria, vacuoles & protein
aggregates, dispersed Golgi, disintegrated
centrosomes
SIL1-interactome Loss of interaction with POC1A and binding to
DNAJB11/ ERj3
Immunoblot analysis of cellular
stress markers
Oxidative- and/ or ER-stress burden
SIL1-SIL1 homomerization Occurrence of degradation products of
pathogenic mutant SIL1-protein which do not
present rapid degradation
mutant of the BiP co-chaperone. On a more general note, our
immunoprecipitation data support the previous description of an
interaction of POC1A with the SIL1-BiP machinery as identified
by BioPlex 2.0 [Biophysical Interactions of ORFEOME-derived
complexes; (28)].
Prompted by the fact POC1A mutations are causative for
a phenotype defined by short stature, onychodysplasia, facial
dysmorphism, and hypotrichosis (SOFT syndrome; 22) and short
stature is also a recurrent clinical finding in MSS patients, effect
of SIL1 expression (wildtype and variant forms) has been studied
and highlighted an increasing effect of elevated SIL1 protein level
on POC1A protein abundance (Figure 5B). Same effect could be
observed for p.R92W and p.K132Q but not p.G312R, p.L457P
or p.V231_I232del mutant forms of SIL1. This effect indicates
that the molecular interaction between the two proteins might
also be of relevance for the clinical manifestation of MSS upon
loss of (functional) SIL1. Given that POC1A links centrosomes
to Golgi assembly and function we further studied level of
FAM134B, a newly identified cis-Golgi protein with a pivotal
role in neuronal function and survival (24) in relation to the
expression of SIL1 wildtype protein. Here same results as for
POC1 could be obtained (Figure 5B) suggesting an impact of
SIL1 expression on the Golgi apparatus, an assumption which
accords with the newly identified SIL1-POC1A interaction and
the results of our further immunofluorescence studies not only
showing a co-localization of SIL1 with POC1A and FAM134B but
also with golgin-97, a known Golgi-marker protein (Figure 5C).
Results of these immunofluorescence-based localization studies
in combination with our immunoprecipitation findings also
suggest that SIL1 localizes (although to a minor degree)
to subcellular compartments beyond the ER. However, to
follow the hypothesis that pathogenic SIL1 variant significantly
impact on function and structure of centrosome and the
Golgi apparatus, ultra-structural studies focussing on their
integrity have been carried out and revealed proliferated and
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dispersed Golgi cisternae as well as centriole-multiplications
and -proliferations in Hek293 cells overexpressing the known
pathogenic forms of SIL1 but not in cells overexpressing the
wildtype or the p.R92W or p.K132Q forms of the protein
(Figures 5D,E). These pathomorphological findings in turn
further support the concept of an impact of SIL1 on Golgi and
centrosome function and integrity and by the same token define
changes in Golgi and centrosome structures as further read-
out measures enabling the evaluation of the pathogenicity of
SIL1 mutations. In this context, it is important to note that
depletion of SIL1 expression in Hek293 cells could be linked to
vulnerability of the Golgi apparatus on both the structural and the
biochemical level (16).
CONCLUSIONS
Generation and subsequent functional, biochemical
and morphological phenotyping of our in vitro models
overexpressing different (benign and pathogenic) forms of the
SIL1 protein allowed to define cellular markers to evaluate
the pathogenicity of SIL1-mutations, an aspect of significant
importance for genetic counseling and genotype-phenotype
correlations. Suitable assays and respective read-out measures
(in terms of cellular biomarkers for pathogenicity of changes in
SIL1 amino acid composition) are summarized in Table 2.
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